



PharmTech.com

ADVANCING DEVELOPMENT AND MANUFACTURING

Enter your Keyword or Phrase Search

- This Site Include Affiliate Sites

[Dosage Forms](#) | [Development](#) | [Manufacturing](#) | [Quality/Regulations](#) | [Analytics](#) | [Outsourcing](#) | [Pharma Marketplace](#)

[Current Issue](#) [Digital Edition](#) [Archive](#) [PharmTech Europe](#) [News](#) [Events](#) [Multimedia](#) [Whitepapers](#) [Webcasts](#) [Magazine App](#)

- News
- PharmTech Talk
- Peer-Reviewed Research
- US Regulatory Watch
- EU Regulatory Watch
- Outsourcing Outlook
- API Synthesis & Manufacturing
- Troubleshooting
- Global Report
- Industry Insider
- Q&A
- Viewpoints
- Inside Standards
- Statistical Solutions

Share

Headspace Moisture Analysis for Determination of Residual Moisture Content in Lyophilized Pharmaceutical Products

Headspace moisture analysis is a rapid non-destructive analytical method that may potentially address the limitations of traditional methods used for residual moisture determination.

Apr 02, 2016 By Derek Duncan
Pharmaceutical Technology
Volume 40, Issue 4, pg 28-31



- Print/Digital
- Newsletters



Partner Resources

Demo Video: Xcellerate® Informatics

[Learn more](#)

Demo Video: Xcellerate® Monitoring

[Learn more](#)

Webinar: Xcellerate® Monitoring: Measuring Success, Challenges, Results & Solutions

[Learn more](#)

eBook: A Dynamic Approach to Managing Risks with Xcellerate® Monitoring

[Learn more](#)

Sponsored by:



Top News

EAG Inc. Rebrands Businesses, Including ABC Labs, as EAG



SIMMISIMONS/GETTY IMAGES

Lyophilization, or freeze-drying, is a process used to stabilize a pharmaceutical formulation and increase the shelflife by removing water from the drug product. During lyophilization, the drug formulation is first frozen and then the ice is removed by sublimation under vacuum during a primary drying phase. A secondary drying phase is then used to remove

unfrozen water molecules at a temperature higher than that used for primary drying. Pharmaceutical freeze drying cycles are designed to remove most of the loosely bound water and to achieve a pharmaceutically elegant cake. For biological materials, it is important to retain a high level of activity in the final product.

Residual moisture content

Determining the residual moisture content of a lyophilized pharmaceutical product is important for several reasons. First, the amount of residual moisture content is related to the stability of the formulation over the shelflife of the product. Small-molecule formulations can have direct degradation pathways triggered by water, and it is crucial that all final product is below a defined residual moisture specification. In general, the degradation pathways for large-molecule formulations are more complex, with water often playing an indirect role. Second, moisture analysis of a statistically relevant sample set can give insight into the freeze-drying process itself. Residual moisture

determination can be used as a tool in process studies to confirm the efficiency, consistency, and robustness of a specific freeze-drying cycle that has been designed for a particular drug formulation.

Typical pharmaceutical freeze-drying cycles usually target residual moisture contents in the range of 1% to 3% water by weight. Historically, a strategy that can be described as “the drier, the better” was often followed. For small molecules having a direct degradation pathway triggered by water, this approach was an appropriate strategy. However, in the world of large biopharmaceutical molecules, it is possible to over-dry. Studies have shown that even in the lyophilized state, proteins depend on small quantities of water to help maintain higher-order structure. Other types of products, such as certain lyophilized blood plasma formulations, need a minimum amount of water to achieve efficient dry-heat viral inactivation. It is therefore sometimes necessary to design a freeze-drying cycle that keeps all product vials within a certain moisture range, having both minimum and maximum specifications.

Historical cycles have often been too conservative (i.e., too long), meaning that the final product was over-dried, because research and development efforts did not take the time to optimize both the formulation and the freeze-drying cycle. Although conservative cycles produce product that meets quality parameters (i.e., sufficiently low residual moisture), the same product quality could be produced with much shorter cycles if appropriate studies are done. Current scientific approaches use various tools to monitor the lyophilization process and analyze the finished product with the goal of defining optimum freeze-drying cycles on a per formulation basis. Data are generated to demonstrate that product quality parameters (such as stability, cake appearance, appropriate reconstitution, and bioactivity) are met in a targeted moisture range and that the defined cycle is robust and consistent in producing product in that moisture range.

Freeze-drying cycle, formulation, and equipment parameters

The residual moisture content depends on both the cycle and the formulation. Focusing on the process side, it is important to control the endpoints of the three lyophilization stages--freezing, primary drying, and secondary drying. Key process parameters are the temperature and pressure gradients chosen for each stage. It is out of the scope of this article to fully treat all the factors that can affect the residual moisture content.

As an example, there are several approaches that can be taken to optimize freezing conditions: annealing, supercooling, and controlled nucleation. The details of crystal formation during freezing have an effect on how efficient the sublimation process is in removing moisture during primary drying. In general, care should be taken in the freezing step to ensure that the product is fully frozen, that the ice crystal structure is open allowing for better sublimation, and that complete freezing is achieved at as high a temperature as possible to save time and energy.

The formulation parameters also have an effect on the final residual moisture content. The exact ice crystal formation and eventual cake structure will depend on the type of pharmaceutical ingredients and buffers in the formulation as well as potentially varying product concentrations. All of these formulation parameters can influence the final residual moisture content achieved by a freeze-drying cycle.

Finally, a third general factor influencing residual moisture content is the equipment and vial configuration used. Vacuum pump, condenser parameters, and the vial size should all be considered when implementing a freeze dryer for particular product batch sizes.

In the end, the final residual moisture content depends on the interplay between the cycle, the formulation, and the equipment parameters. This interplay has motivated the development of approaches for efficient cycle development in recent years. Optimization of the drying cycle for a given formulation requires a balanced understanding of the fundamental science of freeze-drying, formulation characteristics, and equipment capabilities. The ability to make accurate measurements of residual moisture in statistical sample sets of finished product would be a useful tool in these efforts.

1 2 Next »

Recommended Reading

Lyophilization Cycle Optimization of Cell-Derived Products

Laboratories

Sandoz's Biosimilar to Enbrel Gets FDA Support Ahead of Panel


Patheon Announces Initial Public Offering


Federal Court Weighs in on Biosimilar Patent Dance


EMA Releases Statement on Brexit


| More |

Columnists

- 

Outsourcing Outlook
Jim Miller
Bio/Pharma Funding Challenges Could Hurt CDMOs in 2017
- 

Ingredients Insider
Cynthia Challener
Expanding the Chiral Toolbox
- 

Regulatory Watch
Jill Wechsler
FDA and Manufacturers Intensify Concerns about Data Integrity
- 

EU Regulatory Watch
Sean Milmo
Pharmaceuticals in the Environment Spark Controversy



ONLINE AUCTION **GoIndustry DoveBid**
 A LIQUIDITY SERVICES MARKETPLACE



2016 PDA/FDA **PDA** **FDA**
Joint Regulatory Conference
 Sept. 12-14, 2016 | Washington, DC

Outsourcing

EAG Inc. Rebrands Businesses, Including ABC Labs, as EAG Laboratories

EAG Laboratories announces new company identity and intent to expand testing, analysis, and characterization capabilities across multiple markets.

Patheon Announces Initial Public Offering

Patheon launches initial public offering to repay outstanding notes and expenses.

| More |

Webcasts

- **Capsule Filling: Manufacturing Efficiency and the Added Value of Technical Service**
- **Strategies to Accelerate Early Phase Clinical Trials**
- **Trends in Quality Agreements & Communications: A CMO Perspective**

[More Webcasts](#)



Accelerating Reliable ICP-MS Performance

Outstanding reliability, exceptional ease of use, and the industry's lowest operating costs



[Learn more. Click here.](#)



The world's first -70°C walk-in chambers





Sponsored Links

Natoli's Basics of Tablet Manufacturing and Troubleshooting
 — September training course.
Register today!



[About Us](#)
[Contact Us](#)
[Contact Sales](#)
[Advertise](#)

[Contact Editorial](#)
[Editorial Advisory Board](#)
[Author's Guidelines](#)
[eBooks](#)

[Twitter](#)
[RSS](#)
[eNews](#)
[Digital Magazine](#)

[Subscribe](#)
[Terms of Use](#)
[Privacy Policy](#)
[Reprints](#)
[RSS/Linking Policy](#)

[Applied Clinical Trials](#)
[BioPharm International](#)
[CBI](#)
[LCGC / Chromacademy](#)
[Nutritional Outlook](#)
[Pharmaceutical Executive](#)
[Spectroscopy](#)



© 2016 Advanstar Communications Inc. All rights reserved. Reproduction in whole or in part is prohibited.